Zymeworks (ZYME) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 May, 2026Voting matters and shareholder proposals
Election of four directors: Kenneth Galbraith, Susan Mahony, Kelvin Neu, and Scott Platshon, with board recommendation to vote FOR all nominees.
Advisory vote on the compensation of named executive officers, with board recommendation to vote FOR.
Ratification of KPMG LLP as external auditors for the year ending December 31, 2024, with board recommendation to vote FOR.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Shareholders can attend and vote at the meeting in person or by proxy, with detailed instructions provided.
Executive compensation and say-on-pay
Advisory vote on executive compensation is included as a key agenda item.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Zymeworks
- Revenue fell 91% year-over-year, with a net loss of $89.2M and major milestones pending.ZYME
Q2 2026 - Acquisition adds YUPELRI®, diversified assets, and tax benefits, boosting cash flow and value.ZYME
M&A announcement - Zanidatamab nears approval as pipeline assets advance and R&D shifts to novel multi-specifics.ZYME
Jefferies Global Healthcare Conference 2026 - Annual meeting to vote on directors, executive pay, auditor, and highlight ESG and governance.ZYME
Proxy filing - Board recommends approval of all proposals, with strong focus on governance and performance-based pay.ZYME
Proxy filing - Strategy targets royalty growth, $440M milestones, and $125M share buyback for long-term value.ZYME
Investor Update - Q3 revenue up 73% on milestone and royalty gains, with narrowed net loss and strong cash runway.ZYME
Q3 2025 - Zanidatamab advances globally as cash of $395.9M supports a strong pipeline and narrowed losses.ZYME
Q2 2024 - Q1 2025 revenue surged 171% on milestones; cash runway extends into 2H-2027.ZYME
Q1 2025